<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="brief-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">2168-622X</issn><issn pub-type="epub">2168-6238</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10061313</article-id><article-id pub-id-type="pmcid-ver">PMC10061313.1</article-id><article-id pub-id-type="pmcaid">10061313</article-id><article-id pub-id-type="pmcaiid">10061313</article-id><article-id pub-id-type="pmid">36988913</article-id><article-id pub-id-type="doi">10.1001/jamapsychiatry.2023.0310</article-id><article-id pub-id-type="publisher-id">ybr230001</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Association of Receipt of Opioid Use Disorder&#8211;Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic</article-title><alt-title alt-title-type="headline">Association of Receipt of OUD-Related Telehealth Services and Medications for OUD With Fatal Drug Overdoses</alt-title><alt-title alt-title-type="running-head">Association of Receipt of OUD-Related Telehealth Services and Medications for OUD With Fatal Drug Overdoses</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Jones</surname><given-names initials="CM">Christopher M.</given-names></name><degrees>PharmD</degrees><degrees>DrPH</degrees><xref rid="ybr230001aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shoff</surname><given-names initials="C">Carla</given-names></name><degrees>PhD</degrees><xref rid="ybr230001aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blanco</surname><given-names initials="C">Carlos</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="ybr230001aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Losby</surname><given-names initials="JL">Jan L.</given-names></name><degrees>PhD</degrees><degrees>MSW</degrees><xref rid="ybr230001aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ling</surname><given-names initials="SM">Shari M.</given-names></name><degrees>MD</degrees><xref rid="ybr230001aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Compton</surname><given-names initials="WM">Wilson M.</given-names></name><degrees>MD</degrees><degrees>MPE</degrees><xref rid="ybr230001aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="ybr230001aff1"><label>1</label>National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia</aff><aff id="ybr230001aff2"><label>2</label>Office of the Administrator, Centers for Medicare &amp; Medicaid Services, Baltimore, Maryland</aff><aff id="ybr230001aff3"><label>3</label>National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland</aff><aff id="ybr230001aff4"><label>4</label>Centers for Clinical Standards and Quality, Centers for Medicare &amp; Medicaid Services, Baltimore, Maryland</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> January 30, 2023.</p><p content-type="published-online"><bold>Published Online:</bold> March 29, 2023. doi:<uri content-type="doi">10.1001/jamapsychiatry.2023.0310</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2023 Jones CM et al. <italic toggle="yes">JAMA Psychiatry</italic>.</p><corresp id="ybr230001cor1"><bold>Corresponding Author:</bold> Christopher M. Jones, PharmD, DrPH, MPH, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Atlanta, GA 30341 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fjr0@cdc.gov">fjr0@cdc.gov</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Shoff had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Compton and Ling jointly share senior authorship.</p><p><italic toggle="yes">Concept and design:</italic> Jones, Losby, Compton.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> All authors.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Jones, Shoff, Losby.</p><p><italic toggle="yes">Critical revision of the manuscript for important intellectual content:</italic> Jones, Blanco, Losby, Ling, Compton.</p><p><italic toggle="yes">Statistical analysis:</italic> Jones, Shoff.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Ling.</p><p><italic toggle="yes">Supervision:</italic> Jones, Ling, Compton.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Compton reported long-term stock holdings in General Electric Co, 3M Companies, and Pfizer Inc outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This study was sponsored by the Centers for Disease Control and Prevention, the Centers for Medicare &amp; Medicaid Services, and the National Institutes of Health.</p><p><bold>Role of the Funder/Sponsor:</bold> The sponsors supported the authors who were responsible for preparation, review, and approval of the manuscript and the decision to submit the manuscript for publication. The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The sponsor reviewed and approved the manuscript.</p><p><bold>Disclaimers:</bold> The findings and conclusions of this study are those of the authors and do not necessarily reflect the views of the National Institute on Drug Abuse of the National Institutes of Health, the Centers for Disease Control and Prevention, or the US Department of Health and Human Services.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-YBR230001-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2023-03-29T10:00"><day>29</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2023</year></pub-date><volume>80</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">432355</issue-id><fpage>508</fpage><lpage>514</lpage><history><date date-type="received"><day>9</day><month>11</month><year>2022</year></date><date date-type="accepted"><day>30</day><month>1</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>31</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-17 05:25:37.593"><day>17</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright 2023 Jones CM et al. <italic toggle="yes">JAMA Psychiatry</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamapsychiatry-e230310.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamapsychiatry-e230310.pdf">jamapsychiatry-e230310.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archpsyc/fullarticle/10.1001/jamapsychiatry.2023.0310"/><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-ybr230001-1"><title>Question</title><p>Were new federal authorities to expand telehealth use for substance use disorder treatment and to facilitate provision of medications for opioid use disorder (MOUD) during the COVID-19 pandemic associated with a lower risk for fatal drug overdose among Medicare beneficiaries initiating a new episode of opioid use disorder (OUD)&#8211;related care?</p></sec><sec id="ab-ybr230001-2"><title>Findings</title><p>In this cohort study of a prepandemic cohort comprising 105&#8201;162 beneficiaries and a pandemic cohort comprising 70&#8201;479 beneficiaries, receipt of OUD-related telehealth services and receipt of MOUD during the pandemic were associated with reduced odds for fatal drug overdose.</p></sec><sec id="ab-ybr230001-3"><title>Meaning</title><p>This study found that emergency authorized telehealth expansion and MOUD provision during the COVID-19 pandemic were associated with lower odds of fatal drug overdose, demonstrating the potential benefits of continuing these services.</p></sec></abstract><abstract><sec id="ab-ybr230001-4"><title>Importance</title><p>Federal emergency authorities were invoked during the COVID-19 pandemic to expand clinical telehealth for opioid use disorder (OUD).</p></sec><sec id="ab-ybr230001-5"><title>Objective</title><p>To examine the association of the receipt of telehealth services and medications for OUD (MOUD) with fatal drug overdoses before and during the pandemic.</p></sec><sec id="ab-ybr230001-6"><title>Design, Setting, and Participants</title><p>This cohort study used exploratory longitudinal data from 2 cohorts (prepandemic cohort: September 1, 2018, to February 29, 2020; pandemic cohort: September 1, 2019, to February 28, 2021) of Medicare Fee-for-Service beneficiaries aged 18 years or older initiating an episode of OUD-related care using Medicare Fee-for-Service data from the Centers for Medicare &amp; Medicaid Services and National Death Index data from the Centers for Disease Control and Prevention. Data analysis was performed from September 19 to October 17, 2022.</p></sec><sec id="ab-ybr230001-7"><title>Exposures</title><p>Prepandemic vs pandemic cohort demographic, medical, substance use, and psychiatric characteristics.</p></sec><sec id="ab-ybr230001-8"><title>Main Outcomes and Measures</title><p>Receipt of OUD-related telehealth services, receipt of MOUD, and fatal drug overdose.</p></sec><sec id="ab-ybr230001-9"><title>Results</title><p>The prepandemic cohort comprised 105&#8201;162 beneficiaries (58.1% female; 67.6% aged 45-74 years). The pandemic cohort comprised 70&#8201;479 beneficiaries (57.1% female; 66.3% aged 45-74 years). The rate of all-cause mortality was higher in the pandemic cohort (99.9 per 1000 beneficiaries; 7041 deaths) than in the prepandemic cohort (76.8 per 1000; 8076 deaths) (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001). The rate of fatal drug overdoses was higher in the pandemic cohort (5.1 per 1000 beneficiaries; n&#8201;=&#8201;358) than in the prepandemic cohort (3.7 per 1000; n&#8201;=&#8201;391) (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001). The percentage of deaths due to a fatal drug overdose was similar in the prepandemic (4.8%) and pandemic (5.1%) cohorts (<italic toggle="yes">P</italic>&#8201;=&#8201;.49). In multivariable analysis of the pandemic cohort, receipt of OUD-related telehealth was associated with a significantly lower adjusted odds ratio (aOR) for fatal drug overdose (aOR, 0.67; 95% CI, 0.48-0.92) as was receipt of MOUD from opioid treatment programs (aOR, 0.41; 95% CI, 0.25-0.68) and receipt of buprenorphine in office-based settings (aOR, 0.62; 95% CI, 0.43-0.91) compared with those not receiving MOUD; receipt of extended-release naltrexone in office-based settings was not associated with lower odds for fatal drug overdose (aOR, 1.16; 95% CI, 0.41-3.26).</p></sec><sec id="ab-ybr230001-10"><title>Conclusions and Relevance</title><p>This cohort study found that, among Medicare beneficiaries initiating OUD-related care during the COVID-19 pandemic, receipt of OUD-related telehealth services was associated with reduced risk for fatal drug overdose, as was receipt of MOUD from opioid treatment programs and receipt of buprenorphine in office-based settings. Strategies to expand provision of MOUD, increase retention in care, and address co-occurring physical and behavioral health conditions are needed.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study examines the association of the receipt of telehealth services and medications for opioid use disorder (OUD) with fatal drug overdoses before and during the pandemic.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-YBR230001"><title>Introduction</title><p>During the COVID-19 pandemic, federal actions were taken to facilitate access to care for individuals with opioid use disorder (OUD), including expanded telehealth, remote prescribing of buprenorphine, and expanded take-home doses of methadone from opioid treatment programs (OTPs).<sup><xref rid="ybr230001r1" ref-type="bibr">1</xref>,<xref rid="ybr230001r2" ref-type="bibr">2</xref>,<xref rid="ybr230001r3" ref-type="bibr">3</xref>,<xref rid="ybr230001r4" ref-type="bibr">4</xref>,<xref rid="ybr230001r5" ref-type="bibr">5</xref>,<xref rid="ybr230001r6" ref-type="bibr">6</xref></sup></p><p>We previously used a longitudinal 2-cohort study design with Medicare Fee-for-Service (FFS) data from September 2018 to February 2021 to compare the use of telehealth services among Medicare beneficiaries initiating OUD-related care before and during the pandemic.<sup><xref rid="ybr230001r7" ref-type="bibr">7</xref></sup> Use of OUD-related telehealth services during the pandemic was associated with improved retention in use of medications for opioid use disorder (MOUD) and reduced risk for medically treated overdose.<sup><xref rid="ybr230001r7" ref-type="bibr">7</xref></sup> Examining fatal drug overdoses was not possible due to lack of linked Medicare and overdose death data at that time. With the recent availability of linked data through 2021, this follow-up study uses the same 2-cohort longitudinal design to examine the association of receipt of OUD-related telehealth services and MOUD with drug overdose deaths before and during the COVID-19 pandemic.</p></sec><sec id="H1-2-YBR230001"><title>Methods</title><p>Multiple Centers for Medicare &amp; Medicaid Services (CMS) data sources<sup><xref rid="ybr230001r8" ref-type="bibr">8</xref>,<xref rid="ybr230001r9" ref-type="bibr">9</xref></sup> were used (eTable in <xref rid="note-YBR230001-1-s" ref-type="supplementary-material">Supplement 1</xref>). Drug overdose death data from the Centers for Disease Control and Prevention (CDC) National Death Index were linked to Medicare Beneficiary Summary Files. The full details of the cohort design have been provided elsewhere.<sup><xref rid="ybr230001r7" ref-type="bibr">7</xref></sup> In brief, we constructed 2 mutually exclusive cohorts of Medicare FFS beneficiaries aged 18 years or older with OUD, both before and during the pandemic, consisting of individuals starting new (index) episodes of OUD-related care. Individuals already receiving OUD-related services identified by <italic toggle="yes">International Classification of Diseases, Ninth Revision, Clinical Modification</italic> (<italic toggle="yes">ICD-10-CM</italic>) diagnosis codes for OUD during the 6-month cohort preindex period were excluded. The 6-month preindex period (prepandemic cohort: September 2018 to February 2019; pandemic cohort: September 2019 to February 2020) was followed by a 6-month index period (prepandemic cohort: March 2019 to August 2019; pandemic cohort: March 2020 to August 2020) when beneficiaries were enrolled in each cohort, then a 6-month cohort follow-up period (prepandemic cohort: September 2019 to February 2020; pandemic cohort: September 2020 to February 2021)<sup><xref rid="ybr230001r10" ref-type="bibr">10</xref></sup> (eFigure in <xref rid="note-YBR230001-1-s" ref-type="supplementary-material">Supplement 1</xref>). This cohort study was covered by the Common Rule exemption, 45 CFR 46.104(d)(4)(iv), and did not require institutional review board review (ie, the data were deidentified). This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link>) reporting guideline.</p><sec id="H2-1-YBR230001"><title>Outcomes</title><p>The main outcomes were (1) receipt of OUD-related telehealth services; (2) receipt of MOUD (MOUD from OTPs, buprenorphine in office-based settings, extended-release (ER) naltrexone in office-based settings); and (3) fatal drug overdose. Receipt of OUD-related telehealth services was defined as a Medicare Part A or B service claim with OUD diagnosis and telehealth service code, defined by either Place of Service code 02 and/or a combination of Healthcare Common Procedure Coding System (HCPCS) modifier codes and HCPCS or Current Procedural Terminology codes on the claim. Receipt of MOUD from OTPs was defined as having a Part B claim with HCPCS codes corresponding to receipt of MOUD. Receipt of buprenorphine or ER naltrexone in office-based settings was defined as having a Part D pharmacy claim with a National Drug Code for buprenorphine products approved for OUD treatment or for ER naltrexone. Drug overdose deaths were identified with <italic toggle="yes">International Statistical Classification of Diseases and Related Health Problems, Tenth Revision</italic> codes underlying cause of death (X40-44, X60-64, X85, and Y10-14) and occurring after the beneficiary entered the cohort (eTable in <xref rid="note-YBR230001-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p></sec><sec id="H2-2-YBR230001"><title>Statistical Analysis</title><p>Baseline demographic and clinical characteristics were examined by cohort and reported as frequencies and percentages. The number and rate of deaths per 1000 beneficiaries from all causes and the number of deaths due to drug overdose and the percentage of all deaths due to drug overdose were examined by cohort. To assess differences between cohorts, we used the &#967;<sup>2</sup> test for proportions and percentages.</p><p>For the pandemic cohort, a multilevel logistic regression model examined associations between fatal drug overdose during the study period and receipt of OUD-related telehealth services and MOUD. The model was adjusted for baseline characteristics, percentage of days during study period patients received any OUD-related services, and percentage of days patients received any non-OUD&#8211;related services; beneficiary state of residence was included as a level 2 random intercepts parameter to adjust for similarity of beneficiaries residing in the same state. Results are presented as adjusted odds ratios (aORs) and corresponding 95% CIs. Multicollinearity was not identified in final models. Statistical significance was set at <italic toggle="yes">P</italic>&#8201;&lt;&#8201;&#8201;.05, and all <italic toggle="yes">P</italic> values were 2-tailed. Analyses were conducted with SAS Enterprise Guide, version 7.1 (SAS Institute Inc) and Stata, version 17.0 (StataCorp).</p></sec></sec><sec id="H1-3-YBR230001"><title>Results</title><p>The sociodemographic and clinical characteristics of the prepandemic (n&#8201;=&#8201;105&#8201;162) and pandemic (n&#8201;=&#8201;70&#8201;479) cohort beneficiaries are presented in <xref rid="ybr230001t1" ref-type="table">Table 1</xref>. A larger percentage of the beneficiaries in the pandemic cohort received OUD-related telehealth services than beneficiaries in the prepandemic cohort (13&#8201;809 beneficiaries [19.6%] vs 590 beneficiaries [0.6%]; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001). Receipt of MOUD was higher in the pandemic cohort than in the prepandemic cohort (8826 beneficiaries [12.6%] vs 11&#8201;304 beneficiaries [10.8%]; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001).</p><table-wrap position="float" id="ybr230001t1" orientation="portrait"><label>Table 1. </label><caption><title>Baseline Demographic and Clinical Characteristics of Medicare Fee-for-Service Beneficiaries With Opioid Use Disorder, by Cohort</title></caption><table frame="hsides" rules="groups"><col width="39.49%" span="1"/><col width="26.4%" span="1"/><col width="23.74%" span="1"/><col width="10.37%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Beneficiaries, No. (%)<xref rid="ybr230001t1n1" ref-type="table-fn"><sup>a</sup></xref></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic toggle="yes">P</italic> value<xref rid="ybr230001t1n2" ref-type="table-fn"><sup>b</sup></xref></th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Pre&#8211;COVID-19 pandemic cohort</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">COVID-19 pandemic cohort</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cohort size</td><td valign="top" align="left" rowspan="1" colspan="1">105&#8201;162 (59.9)</td><td valign="top" align="left" rowspan="1" colspan="1">70&#8201;479 (40.1)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">61&#8201;108 (58.1)</td><td valign="top" align="left" rowspan="1" colspan="1">40&#8201;227 (57.1)</td><td rowspan="2" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">44&#8201;054 (41.9)</td><td valign="top" align="left" rowspan="1" colspan="1">30&#8201;252 (42.9)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Age group, y</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 18-44</td><td valign="top" align="left" rowspan="1" colspan="1">11&#8201;762 (11.2)</td><td valign="top" align="left" rowspan="1" colspan="1">7774 (11.0)</td><td rowspan="4" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 45-64</td><td valign="top" align="left" rowspan="1" colspan="1">37&#8201;487 (35.6)</td><td valign="top" align="left" rowspan="1" colspan="1">22&#8201;966 (32.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 65-74</td><td valign="top" align="left" rowspan="1" colspan="1">33&#8201;612 (32.0)</td><td valign="top" align="left" rowspan="1" colspan="1">23&#8201;788 (33.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;75</td><td valign="top" align="left" rowspan="1" colspan="1">22&#8201;301 (21.2)</td><td valign="top" align="left" rowspan="1" colspan="1">15&#8201;951 (22.6)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race and ethnicity</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hispanic</td><td valign="top" align="left" rowspan="1" colspan="1">6443 (6.2)</td><td valign="top" align="left" rowspan="1" colspan="1">4417 (6.4)</td><td rowspan="4" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic African American</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8201;382 (11.9)</td><td valign="top" align="left" rowspan="1" colspan="1">7863 (11.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic White</td><td valign="top" align="left" rowspan="1" colspan="1">82&#8201;765 (79.5)</td><td valign="top" align="left" rowspan="1" colspan="1">55&#8201;464 (79.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic other<xref rid="ybr230001t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2478 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1807 (2.6)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">US Census region</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Northeast</td><td valign="top" align="left" rowspan="1" colspan="1">18&#8201;479 (17.6)</td><td valign="top" align="left" rowspan="1" colspan="1">11&#8201;061 (15.7)</td><td rowspan="4" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Midwest</td><td valign="top" align="left" rowspan="1" colspan="1">19&#8201;826 (18.9)</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8201;724 (18.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> South</td><td valign="top" align="left" rowspan="1" colspan="1">41&#8201;642 (39.6)</td><td valign="top" align="left" rowspan="1" colspan="1">29&#8201;089 (41.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> West</td><td valign="top" align="left" rowspan="1" colspan="1">25&#8201;196 (24.0)</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;594 (25.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">County urban-rural status</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Metropolitan</td><td valign="top" align="left" rowspan="1" colspan="1">81&#8201;376 (77.4)</td><td valign="top" align="left" rowspan="1" colspan="1">55&#8201;221 (78.4)</td><td rowspan="3" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Micropolitan</td><td valign="top" align="left" rowspan="1" colspan="1">21&#8201;134 (20.1)</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;594 (19.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Rural</td><td valign="top" align="left" rowspan="1" colspan="1">2644 (2.51)</td><td valign="top" align="left" rowspan="1" colspan="1">1655 (2.4)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Dual status</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicare only</td><td valign="top" align="left" rowspan="1" colspan="1">47&#8201;834 (45.5)</td><td valign="top" align="left" rowspan="1" colspan="1">33&#8201;761 (47.9)</td><td rowspan="2" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicare and Medicaid</td><td valign="top" align="left" rowspan="1" colspan="1">57&#8201;328 (54.5)</td><td valign="top" align="left" rowspan="1" colspan="1">36&#8201;718 (52.1)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Eligibility</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Aged &#8805;65 y</td><td valign="top" align="left" rowspan="1" colspan="1">55&#8201;140 (52.4)</td><td valign="top" align="left" rowspan="1" colspan="1">39&#8201;004 (55.3)</td><td rowspan="3" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Disability</td><td valign="top" align="left" rowspan="1" colspan="1">47&#8201;676 (45.3)</td><td valign="top" align="left" rowspan="1" colspan="1">29&#8201;497 (41.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ESRD</td><td valign="top" align="left" rowspan="1" colspan="1">2346 (2.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1978 (2.8)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Other substance use disorder diagnosis</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Alcohol</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8201;195 (11.6)</td><td valign="top" align="left" rowspan="1" colspan="1">8204 (11.6)</td><td valign="top" align="left" rowspan="1" colspan="1">.78</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Tobacco</td><td valign="top" align="left" rowspan="1" colspan="1">38&#8201;707 (36.8)</td><td valign="top" align="left" rowspan="1" colspan="1">24&#8201;156 (34.3)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cannabis</td><td valign="top" align="left" rowspan="1" colspan="1">7809 (7.4)</td><td valign="top" align="left" rowspan="1" colspan="1">5228 (7.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.95</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cocaine</td><td valign="top" align="left" rowspan="1" colspan="1">4720 (4.5)</td><td valign="top" align="left" rowspan="1" colspan="1">2903 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Stimulant</td><td valign="top" align="left" rowspan="1" colspan="1">5025 (4.8)</td><td valign="top" align="left" rowspan="1" colspan="1">3620 (5.1)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Sedative or hypnotic</td><td valign="top" align="left" rowspan="1" colspan="1">6628 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">4679 (6.6)</td><td valign="top" align="left" rowspan="1" colspan="1">.01</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other psychoactive substance</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8201;339 (11.7)</td><td valign="top" align="left" rowspan="1" colspan="1">7580 (10.8)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;2 Substances</td><td valign="top" align="left" rowspan="1" colspan="1">20&#8201;018 (19.0)</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8201;927 (18.3)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Mental health diagnosis</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Anxiety</td><td valign="top" align="left" rowspan="1" colspan="1">58&#8201;633 (55.8)</td><td valign="top" align="left" rowspan="1" colspan="1">39&#8201;130 (55.5)</td><td valign="top" align="left" rowspan="1" colspan="1">.33</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Bipolar disorder</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;442 (16.6)</td><td valign="top" align="left" rowspan="1" colspan="1">11&#8201;727 (16.6)</td><td valign="top" align="left" rowspan="1" colspan="1">.77</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Major depression</td><td valign="top" align="left" rowspan="1" colspan="1">58&#8201;238 (55.4)</td><td valign="top" align="left" rowspan="1" colspan="1">38&#8201;290 (54.3)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Personality disorder</td><td valign="top" align="left" rowspan="1" colspan="1">6663 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">4260 (6.0)</td><td valign="top" align="left" rowspan="1" colspan="1">.01</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Attention-deficit/hyperactivity disorder</td><td valign="top" align="left" rowspan="1" colspan="1">5317 (5.1)</td><td valign="top" align="left" rowspan="1" colspan="1">3541 (5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">.76</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Posttraumatic stress disorder</td><td valign="top" align="left" rowspan="1" colspan="1">8891 (8.4)</td><td valign="top" align="left" rowspan="1" colspan="1">5951 (8.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.94</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Schizophrenia or other psychotic disorder</td><td valign="top" align="left" rowspan="1" colspan="1">9843 (9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">6928 (9.8)</td><td valign="top" align="left" rowspan="1" colspan="1">.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;2 Mental health diagnoses</td><td valign="top" align="left" rowspan="1" colspan="1">49&#8201;991 (47.5)</td><td valign="top" align="left" rowspan="1" colspan="1">33&#8201;149 (47.0)</td><td valign="top" align="left" rowspan="1" colspan="1">.04</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Other chronic medical conditions</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">11&#8201;334 (10.8)</td><td valign="top" align="left" rowspan="1" colspan="1">7913 (11.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.003</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Diabetes</td><td valign="top" align="left" rowspan="1" colspan="1">38&#8201;042 (36.2)</td><td valign="top" align="left" rowspan="1" colspan="1">25&#8201;523 (36.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.87</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cardiovascular and other circulatory</td><td valign="top" align="left" rowspan="1" colspan="1">81&#8201;056 (77.1)</td><td valign="top" align="left" rowspan="1" colspan="1">54&#8201;130 (76.8)</td><td valign="top" align="left" rowspan="1" colspan="1">.18</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Chronic respiratory disease</td><td valign="top" align="left" rowspan="1" colspan="1">40&#8201;322 (38.3)</td><td valign="top" align="left" rowspan="1" colspan="1">25&#8201;742 (36.5)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Viral hepatitis</td><td valign="top" align="left" rowspan="1" colspan="1">9085 (8.6)</td><td valign="top" align="left" rowspan="1" colspan="1">5447 (7.7)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> HIV</td><td valign="top" align="left" rowspan="1" colspan="1">1434 (1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">963 (1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.96</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Obesity</td><td valign="top" align="left" rowspan="1" colspan="1">38&#8201;722 (36.8)</td><td valign="top" align="left" rowspan="1" colspan="1">25&#8201;511 (36.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.008</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Liver disease cirrhosis and other liver conditions<xref rid="ybr230001t1n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">14&#8201;111 (13.4)</td><td valign="top" align="left" rowspan="1" colspan="1">9698 (13.8)</td><td valign="top" align="left" rowspan="1" colspan="1">.04</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Acute or chronic pain</td><td valign="top" align="left" rowspan="1" colspan="1">93&#8201;548 (89.0)</td><td valign="top" align="left" rowspan="1" colspan="1">61&#8201;861 (87.8)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ESRD, end-stage renal disease; NA, not applicable.</p><fn id="ybr230001t1n1"><label>
<sup>a</sup>
</label><p>Seventy-five beneficiaries were excluded from the study due to dying on the same day as an opioid use disorder index date (40 in the prepandemic cohort and 35 in the pandemic cohort).</p></fn><fn id="ybr230001t1n2"><label>
<sup>b</sup>
</label><p>To assess differences between cohorts, we used the &#967;<sup>2</sup> test for proportions and percentages.</p></fn><fn id="ybr230001t1n3"><label>
<sup>c</sup>
</label><p>Included American Indian or Alaska Native, Asian or Pacific Islander, and other race.</p></fn><fn id="ybr230001t1n4"><label>
<sup>d</sup>
</label><p>Excluding hepatitis.</p></fn></table-wrap-foot></table-wrap><p>The all-cause mortality rate was higher in the pandemic cohort than the prepandemic cohort (99.9 [95% CI, 97.8-102.2] vs 76.8 [95% CI, 75.2-78.5] deaths per 1000 beneficiaries; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001) (<xref rid="ybr230001t2" ref-type="table">Table 2</xref>). The rate of drug overdose deaths was also higher in the pandemic cohort (5.1 [95% CI, 4.6-5.6] deaths per 1000 beneficiaries) than in the prepandemic cohort (3.7 [95% CI, 3.4-4.1] deaths per 1000 beneficiaries) cohort (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001). The percentage of deaths due to drug overdoses did not differ between the cohorts (4.8% (95% CI, 4.4%-5.3%) in the prepandemic cohort and 5.1% (95% CI, 4.6%-5.6%) in the pandemic cohort; <italic toggle="yes">P</italic>&#8201;=&#8201;.49).</p><table-wrap position="float" id="ybr230001t2" orientation="portrait"><label>Table 2. </label><caption><title>All-Cause Mortality and Drug Overdose Mortality Among Medicare Fee-for-Service Beneficiaries With Opioid Use Disorder<xref rid="ybr230001t2n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="31.41%" span="1"/><col width="30.6%" span="1"/><col width="27.82%" span="1"/><col width="10.17%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Type of mortality</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Pre&#8211;COVID-19 pandemic cohort (n&#8201;=&#8201;105&#8201;162)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">COVID-19 pandemic cohort (n&#8201;=&#8201;70&#8201;479)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value<xref rid="ybr230001t2n2" ref-type="table-fn"><sup>b</sup></xref></th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">All-cause mortality</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. of deaths</td><td valign="top" align="left" rowspan="1" colspan="1">8076</td><td valign="top" align="left" rowspan="1" colspan="1">7041</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Rate of death per 1000 beneficiaries (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1">76.8 (75.2-78.5)</td><td valign="top" align="left" rowspan="1" colspan="1">99.9 (97.8-102.2)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Drug overdose mortality</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. of deaths</td><td valign="top" align="left" rowspan="1" colspan="1">391</td><td valign="top" align="left" rowspan="1" colspan="1">358</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Rate of death per 1000 beneficiaries (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1">3.7 (3.4-4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">5.1 (4.6-5.6)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> % of All deaths due to drug overdose (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1">4.8 (4.4-5.3)</td><td valign="top" align="left" rowspan="1" colspan="1">5.1 (4.6-5.6)</td><td valign="top" align="left" rowspan="1" colspan="1">.49</td></tr></tbody></table><table-wrap-foot><fn id="ybr230001t2n1"><label>
<sup>a</sup>
</label><p>Seventy-five beneficiaries were excluded from the study due to dying on the same day as an opioid use disorder index date (40 in the prepandemic cohort and 35 in the pandemic cohort).</p></fn><fn id="ybr230001t2n2"><label>
<sup>b</sup>
</label><p>To assess differences between cohorts, we used the &#967;<sup>2</sup> test for proportions and percentages.</p></fn></table-wrap-foot></table-wrap><p>In the pandemic cohort, a lower adjusted odds of fatal drug overdose was found among beneficiaries receiving OUD-related telehealth services (aOR, 0.67; 95% CI, 0.48-0.92) and those receiving MOUD from OTPs (aOR, 0.41; 95% CI, 0.25-0.68) and buprenorphine in office-based settings (aOR, 0.62; 95% CI, 0.43-0.91) compared with receiving no MOUD (<xref rid="ybr230001t3" ref-type="table">Table 3</xref>). Certain demographic and clinical characteristics were also associated with fatal drug overdoses.</p><table-wrap position="float" id="ybr230001t3" orientation="portrait"><label>Table 3. </label><caption><title>Characteristics Associated With Fatal Drug Overdose During Study Period Among Beneficiaries With Opioid Use Disorder in the Pandemic Cohort<xref rid="ybr230001t3n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="45.64%" span="1"/><col width="31.2%" span="1"/><col width="23.16%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Characteristic</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Beneficiaries, No. (%)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">aOR (95% CI)<xref rid="ybr230001t3n2" ref-type="table-fn"><sup>b</sup></xref></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Receipt of OUD-related telehealth service</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;809 (19.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.67 (0.48-0.92)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Receipt of MOUD during study period</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No MOUD</td><td valign="top" align="left" rowspan="1" colspan="1">61&#8201;626 (87.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> MOUD from OTPs</td><td valign="top" align="left" rowspan="1" colspan="1">2774 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.41 (0.25-0.68)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ER naltrexone in office-based settings</td><td valign="top" align="left" rowspan="1" colspan="1">170 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1.16 (0.41-3.26)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Buprenorphine in office-based settings</td><td valign="top" align="left" rowspan="1" colspan="1">5882 (8.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.62 (0.43-0.91)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">30&#8201;233 (42.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">40&#8201;219 (57.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.54 (0.43-0.68)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline age group, y</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 18-44</td><td valign="top" align="left" rowspan="1" colspan="1">7760 (11.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 45-64</td><td valign="top" align="left" rowspan="1" colspan="1">22&#8201;953 (32.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.84 (0.64-1.11)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 65-74</td><td valign="top" align="left" rowspan="1" colspan="1">23&#8201;788 (33.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.37 (0.25-0.55)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 75 or older</td><td valign="top" align="left" rowspan="1" colspan="1">15&#8201;951 (22.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.14 (0.07-0.28)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline race and ethnicity</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hispanic</td><td valign="top" align="left" rowspan="1" colspan="1">4417 (6.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.78 (0.49-1.23)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic African American</td><td valign="top" align="left" rowspan="1" colspan="1">7862 (11.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.88 (0.62-1.23)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic White</td><td valign="top" align="left" rowspan="1" colspan="1">55&#8201;440 (79.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic other<xref rid="ybr230001t3n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1806 (2.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.90 (0.45-1.80)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline US Census region</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Northeast</td><td valign="top" align="left" rowspan="1" colspan="1">11&#8201;056 (15.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Midwest</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8201;716 (18.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.84 (0.55-1.28)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> South</td><td valign="top" align="left" rowspan="1" colspan="1">29&#8201;078 (41.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.72 (0.49-1.06)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> West</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;591 (25.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.73 (0.46-1.15)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline county urban-rural status</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Metropolitan</td><td valign="top" align="left" rowspan="1" colspan="1">55&#8201;200 (78.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Micropolitan</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;589 (19.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.75 (0.55-1.02)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Rural</td><td valign="top" align="left" rowspan="1" colspan="1">1654 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.78 (0.34-1.79)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline dual status</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicare only</td><td valign="top" align="left" rowspan="1" colspan="1">33&#8201;760 (47.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicare and Medicaid</td><td valign="top" align="left" rowspan="1" colspan="1">36&#8201;692 (52.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1.30 (0.97-1.74)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Time spent in nursing home from baseline to end of study</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No time</td><td valign="top" align="left" rowspan="1" colspan="1">61&#8201;707 (87.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Quantile 1</td><td valign="top" align="left" rowspan="1" colspan="1">2126 (3.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.54 (0.27-1.10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Quantile 2</td><td valign="top" align="left" rowspan="1" colspan="1">2053 (2.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.31 (0.10-0.97)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Quantile 3 or 4</td><td valign="top" align="left" rowspan="1" colspan="1">4566 (6.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.24 (0.10-0.55)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline other substance use disorder diagnosis<xref rid="ybr230001t3n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Alcohol</td><td valign="top" align="left" rowspan="1" colspan="1">8191 (11.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.77-1.32)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Tobacco</td><td valign="top" align="left" rowspan="1" colspan="1">24&#8201;133 (34.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1.65 (1.27-2.13)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cannabis</td><td valign="top" align="left" rowspan="1" colspan="1">5218 (7.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.73 (0.54-0.99)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cocaine</td><td valign="top" align="left" rowspan="1" colspan="1">2894 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1.70 (1.25-2.32)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Stimulant</td><td valign="top" align="left" rowspan="1" colspan="1">3611 (5.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 (0.72-1.38)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Sedative or hypnotic</td><td valign="top" align="left" rowspan="1" colspan="1">4674 (6.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1.68 (1.23-2.29)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other psychoactive substance</td><td valign="top" align="left" rowspan="1" colspan="1">7567 (10.7)</td><td valign="top" align="left" rowspan="1" colspan="1">2.48 (1.90-3.23)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline mental health diagnosis<xref rid="ybr230001t3n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Anxiety</td><td valign="top" align="left" rowspan="1" colspan="1">39&#8201;109 (55.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1.30 (0.99-1.71)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Bipolar disorder</td><td valign="top" align="left" rowspan="1" colspan="1">11&#8201;717 (16.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1.20 (0.91-1.57)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Major depression</td><td valign="top" align="left" rowspan="1" colspan="1">38&#8201;267 (54.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1.03 (0.80-1.32)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Personality disorder</td><td valign="top" align="left" rowspan="1" colspan="1">4258 (6.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1.08 (0.76-1.54)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Attention-deficit/hyperactivity disorder</td><td valign="top" align="left" rowspan="1" colspan="1">3539 (5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.81 (0.56-1.18)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Posttraumatic stress disorder</td><td valign="top" align="left" rowspan="1" colspan="1">5944 (8.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.90 (0.65-1.24)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Schizophrenia or other psychotic disorder</td><td valign="top" align="left" rowspan="1" colspan="1">6923 (9.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.81 (0.59-1.10)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline other chronic medical conditions<xref rid="ybr230001t3n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">7913 (11.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.47 (0.28-0.80)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Diabetes</td><td valign="top" align="left" rowspan="1" colspan="1">25&#8201;521 (36.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1.03 (0.80-1.33)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cardiovascular and other circulatory</td><td valign="top" align="left" rowspan="1" colspan="1">54&#8201;119 (76.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.81 (0.62-1.05)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Chronic respiratory disease</td><td valign="top" align="left" rowspan="1" colspan="1">25&#8201;733 (36.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1.14 (0.90-1.45)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Viral hepatitis</td><td valign="top" align="left" rowspan="1" colspan="1">5441 (7.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1.52 (1.15-2.00)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> HIV</td><td valign="top" align="left" rowspan="1" colspan="1">963 (1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.65 (0.33-1.31)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Obesity</td><td valign="top" align="left" rowspan="1" colspan="1">25&#8201;506 (36.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.71 (0.55-0.91)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Liver disease cirrhosis and other liver conditions<xref rid="ybr230001t3n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">9696 (13.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1.22 (0.92-1.62)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Acute or chronic pain</td><td valign="top" align="left" rowspan="1" colspan="1">61&#8201;874 (87.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.63 (0.48-0.82)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">% of Days receiving care from baseline to end of study or death</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> OUD-related care</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">1.04 (1.03-1.05)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-OUD&#8211;related care</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (1.01-1.02)<xref rid="ybr230001t3n3" ref-type="table-fn"><sup>c</sup></xref></td></tr></tbody></table><table-wrap-foot><p>Abbreviations: aOR, adjusted odds ratio; ER, extended release; MOUD, medications for opioid use disorder; NA, not applicable; OTP, opioid treatment program; OUD, opioid use disorder.</p><fn id="ybr230001t3n1"><label>
<sup>a</sup>
</label><p>To enable mutually exclusive groups for the regression analysis, 27 beneficiaries (0.30% of beneficiaries receiving MOUD) who received both buprenorphine and ER naltrexone from pharmacies during the study period were excluded from the analysis. Also, 75 beneficiaries were excluded from the study due to dying on the same day as an opioid use disorder index date (40 in the prepandemic cohort and 35 in the pandemic cohort).</p></fn><fn id="ybr230001t3n2"><label>
<sup>b</sup>
</label><p>Models adjusted for all variables.</p></fn><fn id="ybr230001t3n3"><label>
<sup>c</sup>
</label><p><italic toggle="yes">P</italic>&#8201;&#8804;&#8201;.05.</p></fn><fn id="ybr230001t3n4"><label>
<sup>d</sup>
</label><p>Included American Indian or Alaska Native, Asian or Pacific Islander, and other race.</p></fn><fn id="ybr230001t3n5"><label>
<sup>e</sup>
</label><p>Reference group does not have a condition.</p></fn><fn id="ybr230001t3n6"><label>
<sup>f</sup>
</label><p>Excluding hepatitis.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H1-4-YBR230001"><title>Discussion</title><p>Medicare beneficiaries starting a new episode of OUD-related care during the pandemic who received OUD-related telehealth services had a 33% lower adjusted odds of a fatal drug overdose, even after accounting for OUD and non-OUD care engagement and receipt of MOUD. This is consistent with our previous study that found OUD-related telehealth services were associated with reduced risk for nonfatal overdose.<sup><xref rid="ybr230001r7" ref-type="bibr">7</xref></sup> We also found that receipt of MOUD from OTPs and receipt of buprenorphine in office-based settings were associated with 59% and 38% lower adjusted odds of fatal drug overdose, respectively. In contrast, consistent with prior research,<sup><xref rid="ybr230001r11" ref-type="bibr">11</xref>,<xref rid="ybr230001r12" ref-type="bibr">12</xref></sup> receipt of ER naltrexone was not associated with a lower risk for overdose death, nor with a lower risk for nonfatal overdose in our prior study.<sup><xref rid="ybr230001r7" ref-type="bibr">7</xref></sup></p><p>All-cause mortality and drug overdose deaths were higher in the pandemic cohort compared with the prepandemic cohort. This increase in overdose deaths among the pandemic cohort is consistent with national trends showing a 31% increase in overdose deaths between 2019 and 2020.<sup><xref rid="ybr230001r13" ref-type="bibr">13</xref></sup></p><p>Despite encouraging findings associated with telehealth and MOUD, only 1 in 5 Medicare beneficiaries in our pandemic cohort received OUD-related telehealth services, and only 1 in 8 received MOUD, underscoring the need for continued expansion of these potentially life-saving interventions across clinical settings.<sup><xref rid="ybr230001r14" ref-type="bibr">14</xref>,<xref rid="ybr230001r15" ref-type="bibr">15</xref></sup> In addition, our study highlights several findings for future research. For example, exploring why tobacco use disorders were associated with an increased risk, cannabis use disorders with a decreased risk, and alcohol use disorders not associated with a risk for fatal overdose is warranted. Similarly, cancer, obesity, and pain diagnoses were all associated with a lower risk for fatal overdose.</p><sec id="H2-3-YBR230001"><title>Limitations</title><p>Our study contains Medicare FFS beneficiaries that sought and received care before and during the pandemic; the findings might not generalize to Medicare populations not seeking services or to other populations. Our study required individuals to have an <italic toggle="yes">ICD-10-CM</italic> OUD diagnosis code; it is possible that some individuals with OUD were not recorded with an OUD diagnosis and thus not included in this study. The provision of telehealth may be underestimated because differential uptake by clinicians and health systems of telehealth billing codes added during the initial phases of the pandemic may have occurred. Given the observational nature of the study, we cannot draw causal inferences.</p></sec></sec><sec id="H1-5-YBR230001"><title>Conclusions</title><p>This cohort study found that receipt of OUD-related telehealth services was associated with a reduced risk for fatal drug overdose, as was receipt of MOUD from OTPs and receipt of buprenorphine in office-based settings, demonstrating the potential benefits of continuing these services.</p></sec></body><back><ref-list id="REF-YBR230001"><title>References</title><ref id="ybr230001r1"><label>1</label><mixed-citation publication-type="webpage">Public health emergency. Determination that a public health emergency exists. US Department of Health and Human Services. January 31, 2020. Accessed February 17, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx" ext-link-type="uri">https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx</ext-link></mixed-citation></ref><ref id="ybr230001r2"><label>2</label><mixed-citation publication-type="webpage">COVID-19 disaster declarations. Federal Emergency Management Agency (FEMA). Accessed February 17, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fema.gov/disaster/coronavirus/disaster-declarations" ext-link-type="uri">https://www.fema.gov/disaster/coronavirus/disaster-declarations</ext-link></mixed-citation></ref><ref id="ybr230001r3"><label>3</label><mixed-citation publication-type="webpage">Medicare payment policies during COVID-19. Centers for Medicare and Medicaid Services. Accessed February 17, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://telehealth.hhs.gov/providers/billing-and-reimbursement/medicare-payment-policies-during-covid-19/" ext-link-type="uri">https://telehealth.hhs.gov/providers/billing-and-reimbursement/medicare-payment-policies-during-covid-19/</ext-link></mixed-citation></ref><ref id="ybr230001r4"><label>4</label><mixed-citation publication-type="journal">Chu RC, Peters C, De Lew N, Sommers BD. Issue brief: state Medicaid telehealth policies before and during the COVID-19 public health emergency. Assistance Secretary for Planning and Evaluation (ASPE). July 2021. Accessed February 17, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://aspe.hhs.gov/sites/default/files/2021-07/medicaid-telehealth-brief.pdf" ext-link-type="uri">https://aspe.hhs.gov/sites/default/files/2021-07/medicaid-telehealth-brief.pdf</ext-link></mixed-citation></ref><ref id="ybr230001r5"><label>5</label><mixed-citation publication-type="webpage">Opioid treatment program (OTP) guidance. March 16, 2020. Substance Abuse and Mental Health Services Administration (SAMHSA). Accessed February 17, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf" ext-link-type="uri">https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf</ext-link></mixed-citation></ref><ref id="ybr230001r6"><label>6</label><mixed-citation publication-type="webpage">U.S. Department of Justice/Drug Enforcement Administration. Dear Registrant: [This letter only addresses the topic of prescribing buprenorphine for maintenance and detoxification treatment.]. Accessed February 17, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf" ext-link-type="uri">https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf</ext-link></mixed-citation></ref><ref id="ybr230001r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Shoff</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hodges</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among beneficiaries before and during the COVID-19 pandemic</article-title>. <source>JAMA Psychiatry</source>. <year>2022</year>;<volume>79</volume>(<issue>10</issue>):<fpage>981</fpage>-<lpage>992</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2022.2284</pub-id><pub-id pub-id-type="pmid">36044198</pub-id><pub-id pub-id-type="pmcid">PMC9434479</pub-id></mixed-citation></ref><ref id="ybr230001r8"><label>8</label><mixed-citation publication-type="webpage">Master Beneficiary Summary File (MBSF) Base. Centers for Medicare &amp; Medicaid Services. Research Data Assistance Center. Accessed February 17, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://resdac.org/cms-data/files/mbsf-base" ext-link-type="uri">https://resdac.org/cms-data/files/mbsf-base</ext-link></mixed-citation></ref><ref id="ybr230001r9"><label>9</label><mixed-citation publication-type="webpage">Master Beneficiary Summary File (MBSF): 27 CCW Chronic Conditions Segment. Centers for Medicare &amp; Medicaid Services. Research Data Assistance Center. Accessed February 17, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://resdac.org/cms-data/files/mbsf-27-cc" ext-link-type="uri">https://resdac.org/cms-data/files/mbsf-27-cc</ext-link></mixed-citation></ref><ref id="ybr230001r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Nunes</surname><given-names>EV</given-names></string-name>, <string-name name-style="western"><surname>Bisaga</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Levin</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>Olfson</surname><given-names>M</given-names></string-name></person-group>. <article-title>Development of a Cascade of Care for responding to the opioid epidemic</article-title>. <source>Am J Drug Alcohol Abuse</source>. <year>2019</year>;<volume>45</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00952990.2018.1546862</pub-id><pub-id pub-id-type="pmid">30675818</pub-id><pub-id pub-id-type="pmcid">PMC6404749</pub-id></mixed-citation></ref><ref id="ybr230001r11"><label>11</label><mixed-citation publication-type="book">National Academies of Sciences, Engineering, and Medicine. <source>Medications for Opioid Use Disorder Save Lives</source>. <publisher-name>National Academies Press</publisher-name>; <year>2019</year>. <pub-id pub-id-type="pmid">30896911</pub-id></mixed-citation></ref><ref id="ybr230001r12"><label>12</label><mixed-citation publication-type="webpage">Medications for Opioid Use Disorder: Treatment Improvement Protocol (TIP) 63. Substance Abuse and Mental Health Services Administration (SAMHSA). Updated 2021. Accessed February 17, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf" ext-link-type="uri">https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf</ext-link></mixed-citation></ref><ref id="ybr230001r13"><label>13</label><mixed-citation publication-type="book"><person-group><string-name name-style="western"><surname>Hedegaard</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mini&#241;o</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Spencer</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Warner</surname><given-names>M</given-names></string-name></person-group>. Drug overdose deaths in the United States, 1999&#8211;2020. NCHS Data Brief. No. 428. <publisher-name>National Center for Health Statistics</publisher-name>; <year>2021</year>. </mixed-citation></ref><ref id="ybr230001r14"><label>14</label><mixed-citation publication-type="webpage">CMS Behavioral Health Strategy. Centers for Medicare and Medicaid Services (CMS). Last modified May 5, 2022. Accessed February 17, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cms.gov/cms-behavioral-health-strategy" ext-link-type="uri">https://www.cms.gov/cms-behavioral-health-strategy</ext-link></mixed-citation></ref><ref id="ybr230001r15"><label>15</label><mixed-citation publication-type="webpage">Overdose Prevention Strategy. US Department of Health and Human Services. Accessed February 17, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hhs.gov/overdose-prevention/" ext-link-type="uri">https://www.hhs.gov/overdose-prevention/</ext-link></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-YBR230001-1"><supplementary-material id="note-YBR230001-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p><bold>eFigure.</bold> Cohort Pre-Index, Index, and Follow-up Periods for the Pre-Pandemic and Pandemic Cohorts</p><p><bold>eTable.</bold> Definitions and Billing Codes Used for OUD, Medications for Opioid Use Disorder, Telehealth, Fatal Drug Overdose, and Other Conditions and Services Received</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamapsychiatry-e230310-s001.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p>
Data Sharing Statement
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamapsychiatry-e230310-s002.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></notes></back></article></pmc-articleset>